We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
+10.39%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$665M
AUM Growth
+$105M
Cap. Flow
+$47.8M
Cap. Flow %
7.2%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$22.1M
2
ESPR
Esperion Therapeutics
ESPR
+$20.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$4.88M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$498M 74.97%
20,229,713
+1,046,000
+5% +$22.1M
ALKS icon
2
Alkermes
ALKS
$8.82B
$59.7M 8.99%
1,030,639
– –
ESPR
3
DELISTED
Esperion Therapeutics
ESPR
$26.2M 3.94%
+566,000
New +$20.8M
SPXU icon
4
ProShares UltraPro Short S&P 500
SPXU
$436M
$19.2M 2.9%
3,075
– –
SDS icon
5
ProShares UltraShort S&P500
SDS
$406M
$16M 2.4%
12,600
– –
EPI icon
6
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$15.4M 2.32%
630,000
– –
INDA icon
7
iShares MSCI India ETF
INDA
$6.71B
$15.4M 2.32%
480,000
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$2.77B
$14.3M 2.16%
386,667
+110,274
+40% +$4.88M

Similar funds

BHCM
Boulder Hill Capital Management New York $47.9M AUM
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
BHH
Baker Hughes Holdings Houston, Texas $47.6M AUM 26.35% 1-Year Est. Return
LAMC
Lubert-Adler Management Company Philadelphia, Pennsylvania $49.3M AUM 17.46% 1-Year Est. Return
MAM
Miria Asset Management St. Julians, Malta $49.9M AUM 21.84% 1-Year Est. Return
BCM
BlueMar Capital Management Miami, Florida $49.9M AUM 28.76% 1-Year Est. Return
LOF
Lightspeed Opportunity Fund Menlo Park, California $50.1M AUM 53.1% 1-Year Est. Return
CLCM
Center Lake Capital Management West Palm Beach, Florida $45.8M AUM 58.23% 1-Year Est. Return

Meditor Group's Q2 2017 Portfolio in Review

As of Q2 2017, Meditor Group held 8 positions worth $665M, up 19% from $559M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group deployed $47.8M of net new capital in Q2 2017, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Esperion Therapeutics: 566,000 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier.

  • Meditor Group's largest Q2 2017 buy was Esperion Therapeutics: 566,000 shares worth $26.2M.
  • Meditor Group added most to Exelixis in Q2 2017, an estimated $22.1M increase.
  • Meditor Group's ten largest holdings make up 100% of its $665M portfolio in Q2 2017.
  • Meditor Group opened 1 new position and closed 0 in Q2 2017.
  • Meditor Group's portfolio value rose 19% quarter-over-quarter to $665M.

Based on Meditor Group's 13F filing for Q2 2017, filed 21 Jul 2017.